Skip to main content

Table 4 Current laboratory tests and drug therapy of childhood-onset systemic lupus erythematosus (cSLE) according to the presence of diffuse alveolar hemorrhage (DAH)

From: Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: a severe disease flare with serious outcome

Variables

With DAH (at diagnosis)

(n = 19)

Without DAH (at last visit)

(n = 76)

P

Current laboratory exams

 Autoimmune hemolytic anemia

5 (26)

8 (10)

0.127

 Thrombocytopenia, < 150,000/mm3, n = 93

10 (52)

9/74 (12)

< 0.0001*

 Anti-ds-DNA, n = 75

8/13 (61)

30/62 (48)

0.544

Drug therapy

 Prednisone current dose, mg/Kg, n = 82

1.4 (0.3–2)

0.5 (0.03–3)

< 0.0001*

 Intravenous methylprednisolone

18 (95)

12 (15)

< 0.0001*

 Antimalarial drugs

14 (74)

41 (54)

0.193

 Azathioprine

2 (10)

16 (21)

0.513

 Mycophenolate mofetil

1 (5)

5 (6)

1.000

 Intravenous cyclophosphamide

9 (47)

6 (8)

< 0.0001*

  1. *P-value according to Bonferroni correction for multiple comparisons (p < 0.0022). Results are presented in n (%) and median (range), anti-ds-DNA – anti-double-stranded DNA antibodies
Back to article page

Advances in Rheumatology

ISSN: 2523-3106